Could nerve growth factor inhibitors have a place in the treatment of knee osteoarthritis?: Impact of joint destruction and means of administration ossn the value of Tanezumabs  by Losina, E. et al.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A394ﬁndings clearly indicate that even in low-risk group, it is cost-effective
to co-prescribe PPIs along with traditional or COX-2-selective NSAIDs.
Our results should be interpreted with caution due to their short time
horizon and may not generalize beyond 3 months.
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Purpose: Tanezumab is a nerve growth factor inhibitor in development
as an analgesic for patients with knee osteoarthritis (OA). While several
studies show promising pain relief with Tanezumab, reports of joint
destruction have led to temporary suspension of further studies. We
sought to establish cost and toxicity (joint destruction) thresholds that
would make Tanezumab a cost-effective treatment for moderate to
severe knee OA.
Methods:We used the Osteoarthritis Policy (OAPol) model, a validated
computer simulation model of the natural history and management of
knee OA, to estimate the cost-effectiveness of using Tanezumab in
patients with persistent pain despite currently available pharmacologic
therapy. Population characteristics and efﬁcacy were derived from Lane
et al. (2010). Mean age was 59 years, 59% were female and 88% were
white. Baseline WOMAC Pain (0-100, with 100¼worst) was 67 (SD 13).
Mean pain reduction from Tanezumabwas 34 (SD 20) in the ﬁrst year of
treatment. In the absence of long-term data, we estimated Tanezumab
annual discontinuation rate after the ﬁrst year at 10% using data on
Enbrel in RA. In the base case, we assumed joint destruction in 1% of
subjects based on data from Pﬁzer’s 2012 Arthritis Advisory Committee
Brieﬁng Document. In subjects with a destroyed joint, we assumed a
50% decrease in pain reduction and structural efﬁcacy for primary and
revision total knee replacement surgery (TKR). We included drug,
administration, and monitoring costs of Tanezumab. The price of one
dose of Tanezumab (delivered every 8 weeks) was varied from $200 to
$1,000. For each dose price, we considered self-administered subcuta-
neous injections vs. provider-administered IV infusion. The cost of an IV
infusion varies by setting (non-hospital vs. hospital) and by whether it
is billed as chemotherapy. Administrative costs therefore varied from $0
to $346 per dose in this analysis. Annual monitoring costs for IV infu-
sions were ﬁxed at $250 and included 2x/yr MD visits, 1x/yr blood tests,
and biannual X-rays to check for OA progression. Monitoring costs for
subcutaneous injections were $442, for two additional MD visits/yr.
Cost-effectiveness was estimated as the ratio of incremental costs to
incremental effectiveness (quality-adjusted life years, QALYs) when
Tanezumab was added to current treatment for knee OA prior to pri-
mary TKR. Costs and QALYs were discounted at 3% per year. We deﬁned
a program as “cost-effective” if its cost-effectiveness ratio was below
$100,000/QALY. In sensitivity analyses we varied efﬁcacy, discontinua-
tion, joint destruction rates and costs of Tanezumab.
Results: In the base case analysis, Tanezumab led to an additional 0.27
quality-adjusted life years. It reduced primary TKR utilization by 17%
and revision TKR utilization by 29%, and increased mean age at TKR
from 67 to 70 years. Green shading in the Table indicates scenarios in
which Tanezumab was cost-effective. Subcutaneous Tanezumab at
$600/dose remained cost-effective when efﬁcacy decreased by 20% and
when discontinuation increased to 20%. Subcutaneous Tanezumab at
$600/dose also remained cost-effective at a 2% joint destruction rate,
but not when the joint destruction rate was increased to 5%. At joint
destruction rates above 10%, Tanezumab decreased quality-adjusted life
expectancy and did not represent a viable treatment option.Conclusions: Tanezumab (a promising NGF inhibitor in development)
could be a cost-effective treatment for moderate to severe knee OA pain
depending on the price of the drug and the delivery means. The value of
Tanezumab depends on the rate of joint destruction.
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EFFECTS OF DOXYCYCLINE AS AN ADJUVANT THERAPY ON THE
WOMAC INDEX OF PATIENTS WITH PRIMARY KNEE
OSTEOARTHRITIS
S. Salman, A.M. Ahmed. Coll. of Med., Baghdad, Iraq
Purpose: To examine the short-term effects of doxycycline compared
with placebo on the WOMAC index (Western Ontario and McMaster
Universities) of knee osteoarthritis during a 3-month treatment course.
Methods:One hundred forty patients were enrolled in this randomized,
placebo-controlled, double blind study. Half the patients (70) were
randomly assigned to receive oral doxycycline capsule 100 mg twice
daily in the drug group and the other half received a starch containing
capsule (the placebo group). The efﬁcacy outcome measure was the
change in the WOMAC index.
Results: There were no signiﬁcant differences between the drug and
placebo groups in pain score at the baseline visit (P¼0.63) or at the ﬁrst
visit one month later (P¼0.29). However, at the second visit, there was a
signiﬁcant reduction in pain score in the drug group compared to both
placebo group (P¼0.028) and the baseline scores. At the third visit,
three months later, the difference between both groups became more
signiﬁcant (P¼0.013). Stiffness and physical function scores in all
comparisons in different visits showed no signiﬁcant differences
between both study groups.Mean WOMAC scores were reduced at each
visit compared to its baseline value in drug group compared to the
placebo group, and the reduction in mean score of baseline vs. third
visit was signiﬁcantly much higher in the treatment group (8.37±2.1)
vs. (3.83±3.1) respectively, P<0.001.
Conclusions: Doxycycline at the oral twice-daily dosage of 100 mg has
symptomatic beneﬁt in patients with primary osteoarthritis of the
knees in terms of pain reduction and total WOMAC score.
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MRI ANALYSIS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS;
TREATMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS WITH ORAL
SALMON CALCITONIN
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Purpose: To evaluate the structuremodiﬁcation efﬁcacy in two phase III
studies by MRI of Oral Salmon Calcitonin (sCT) in osteoarthritis (OA)
patients with moderate to severe knee pain and joint structural damage
classiﬁed as Kellgren-Lawrence 2-3.
Methods: This is the combined reporting of two randomized, double-
blind, multi-center, placebo-controlled trials (CSMC021C2301 and
CSMC021C2302), evaluating the efﬁcacy and safety of sCT in patients
with painful knee OA, enrolling 1,176 and 1,030 patients, respectively,
total of 2206, of which 858 were included in the MRI knee sub-
population (demographics table 1). sCT was formulated with a 5-CNAC
carrier (a molecule based on Eligen® technology). MRIs were acquired
at four investigator sites using a Turbo 3D T1 sequence on a 0.18T Esaote
scanner (40 FA, TR 50ms, TE 16ms, scan time 10 minutes, resolution
0.7mm x 0.7mm x 0.8mm). The sequence was optimized for cartilage
visualization. Cartilage volumes were automatically quantiﬁed in the
medial tibial and the medial femoral compartments using a computer-
based method (KneeIQ). The volume scores were corrected for scanner
drift. The subjects had painful knee OA with structural manifestations.
Study subjects were randomized (1:1) to oral sCT 0.8 mg twice daily or
placebo for 24 months. This is the ﬁrst reporting of the combined
studies on the ﬁrst secondary endpoint, MRI.
Results: At the 24 month endpoint there was a signiﬁcant protection of
MRI total cartilage volume loss (P<0.02) in CSMC021C2301 albeit not in
CSMC021C2302 (P¼0.67), and not combined, ﬁgure 1.
Conclusions: The present formulation of oral calcitonin did not provide
reproducible clinical beneﬁts in patients with symptomatic knee OA
(NCT00486434, NCT00704847). Other formulations of calcitonin
receptor agonists in a selected subpopulation ﬁtting the mode of action
